Hutchison China MediTech (Chi-Med) to Outsource Development of a TCM

Published: Dec 28, 2009

ChinaBio Today -- Hutchison Chi-Med will collaborate with the University of Cambridge in the UK to investigate the mechanism of one of its best-selling TCMs, the patented Shexiang Baoxin pill that is prescribed for heart disease. The SXBX pill is thought to have an angiogenesis effect. Dysfunctional angiogenesis is associated with more than 80 diseases, from cancer and diabetic eye problems to stroke. More details...

Back to news